The severity of ALS correlates with how badly mutations destabilize superoxide dismutase 1, and promote its aggregation, according to a new study.
By beaming red light at a blood sample and measuring the scattered photons, scientists claim to identify people with Alzheimer’s disease.
Two trials suggest that a fixed combination of a cough medicine and a cardiac arrhythmia medicine might treat agitation and quiet emotional outbursts in people with Alzheimer’s.
People with moderate to severe Alzheimer’s have higher levels of orexin, a neuropeptide that keeps people awake, a study reports. The findings solidify links between orexin and sleep disturbances associated with the disease.
Aβ oligomers rapidly seed tau pathology in macaques, potentially providing a model for drug testing that better reflects human pathology.Aβ oligomers rapidly seed tau pathology in macaques, potentially providing a model for drug testing that better reflects human pathology.
Stopping Familial Alzheimer's—Woman at Risk Has Healthy Twins A New Drug to Calm Agitation, Uncontrollable Laughing and Crying, in Alzheimer’s? Does Shining Laser Light on Blood Reflect Alzheimer’s? American Neurological Association: 2014 Annual ...
Using a rarely implemented in vitro fertilization procedure, a woman whose family carries a presenilin mutation delivered twins who are virtually assured of escaping early onset Alzheimer’s disease.
Introducing a clinical trials database for ALS that encompasses nearly 9,000 patient records, the organizers tease with the first few findings.
Amyloid plaques and tau tangles sprout in human neuron cultures grown in a supportive gel. Researchers think this system may closely model human disease and aid in drug discovery.
Therapeutics that target γ-secretase produced different results in human neurons and mouse models of Alzheimer’s disease.
Results suggest the drug boosts cognition when given alongside the acetylcholinesterase inhibitor.
ALS-linked optineurin works closely with Parkinson’s-associated Pink1 and parkin in a pathway that recycles mitochondria.
The pharma giant puts up funding to help develop AstraZeneca’s inhibitor, the second such compound to enter Phase 2 testing.
A study claims that two genetic variants combined may hasten cognitive decline in people who have Aβ deposits in the brain.
A new assay detects tau and α-synuclein seeds in human brain samples. Could it become a diagnostic?